Camidanlumab Tesirine, An Antibody-Drug Conjugate, In Relapsed/Refractory CD25-Positive Acute Myeloid Leukemia Or Acute Lymphoblastic Leukemia: A Phase I Study

Leukemia Research
10 Jul, 2020 ,

Aaron D.Goldberg conducted a study to safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory acute lymphoblastic leukemia/acute myeloid leukemia. The researchers concluded that  signal for serious immune-related adverse eventss such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule.